Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 20/20 | 0.65 |
| ▸ | PIM1 | P11309 | 18/20 | 0.65 |
| ▸ | PIM3 | Q86V86 | 18/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17136329 | 0.94 | PIM2 (0.60) | PIM2PIM1PIM3 | |
| SCHEMBL17136286 | 0.92 | PIM2 (0.66) | PIM2PIM1PIM3 | |
| SCHEMBL17136289 | 0.87 | PIM3 (0.64) | PIM2PIM1PIM3 | |
| SCHEMBL17136323 | 0.87 | PIM2 (0.62) | PIM2PIM1PIM3 | |
| Hydrochloric Acid SCHEMBL18695492 | 0.87 | PIM3 (0.63) | PIM2PIM1PIM3 | |
| SCHEMBL18652637 | 0.86 | PIM2 (0.53) | PIM2PIM1PIM3 | |
| SCHEMBL17136300 | 0.86 | PIM1 (0.74) | PIM2PIM1PIM3 | |
| SCHEMBL18659492 | 0.85 | PIM3 (0.60) | PIM2PIM1PIM3 | |
| Hydrochloric Acid SCHEMBL18695497 | 0.84 | PIM3 (0.60) | PIM2PIM1PIM3 | |
| SCHEMBL17136331 | 0.83 | PIM1 (0.65) | PIM2PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. | 2015-10-08 | — | — | US | claimed |
| WO-2017045615-A1 | PYRIDINE DERIVATIVE PIM KINASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE PREPARATION | 上海吉铠医药科技有限公司 | 2017-03-23 | — | — | WO | disclosed |
| US-9452995-B2 | Pyridine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2016-09-27 | — | — | US | disclosed |
| US-9452995-B2 | Pyridine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2016-09-27 | — | — | US | disclosed |
| US-9452995-B2 | Pyridine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2016-09-27 | — | — | US | disclosed |
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.